Yam Code

New Paste Browse

https://www.selleckchem.com/products/apo866-fk866.html PURPOSE To examine an association between gestational weight gain (GWG), defined by the Institute of Medicine (IOM) guidelines, and surgical site infections in obese women. METHODS This was a retrospective study of all obese women with singleton pregnancies undergoing cesarean delivery at ≥ 23 weeks' gestation between January 2012 and June 2018. Women were categorized according to GWG below, within, and above the IOM guidelines. Our primary outcome was a composite of surgical site infections. Coarsened Exact Matching with k-to-k solution was performed using predefined variables. RESULTS Of 2376 obese women, 429 (18.1%), 449 (18.9%), and 1498 (63.0%) had GWG below, within, and above the IOM guidelines, respectively. After matching, there was no difference in a rate of the primary outcome between women with GWG below the IOM guidelines and those with GWG within the IOM guidelines (6.7% [20/300] vs 4.3% [13/300]; P = .21). Similarly, there was no difference in the rate of the primary outcome between women with GWG above the IOM guidelines and those with GWG within the IOM guidelines (5.7% [24/421] vs 5.2% [22/421]; P = .76). CONCLUSION Among obese women, GWG was not associated with surgical site infections.PURPOSE Peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-DOTA0,TYR3-octreotate ([177Lu]Lu-DOTA-TATE) and the mechanistic target of rapamycin (mTOR) inhibitor everolimus are both approved for the treatment of neuroendocrine tumours (NET). However, tumour progression is still frequent, and treatment strategies need further improvement. One possible approach could be to combine different therapy options. In this study, we investigated the toxicity of a combined treatment with everolimus and [177Lu]Lu-DOTA-TATE in female Lewis rats. METHODS Animals received 200 MBq of [177Lu]Lu-DOTA-TATE once and/or 5 mg/kg body weight everolimus or placebo weekly for 16 weeks and were divided into four groups (group 1, pl

Paste Settings

Paste Title : [Optional]

Paste Folder : [Optional]

Syntax Highlighting : [Optional]

Paste Expiration : [Optional]

Paste Status : [Optional]

Password : [Optional]

Description: [Optional]

Tags: [Optional]

Encrypt Paste (?)

You are currently not logged in, this means you can not edit or delete anything you paste. Sign Up or Login

Paste Settings

Site Languages